Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study

Objectives. This 5-yr study assessed urate-lowering and clinical efficacy and safety of long-term febuxostat therapy in subjects with gout. The primary efficacy end-point was reduction to and maintenance of serum urate (sUA) levels

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2009-02, Vol.48 (2), p.188-194
Main Authors: Schumacher, H. R., Becker, M. A., Lloyd, E., MacDonald, P. A., Lademacher, C.
Format: Article
Language:English
Subjects:
Adult
Aged
Allopurinol
Biological and medical sciences
Biomarkers - blood
Clinical Trials, Phase II as Topic
Diseases of the osteoarticular system
Febuxostat
Female
Follow-Up Studies
Gout
Gout - blood
Gout - drug therapy
Gout - pathology
Gout Suppressants - therapeutic use
Humans
Hyperuricaemia
Inflammatory joint diseases
Joints - pathology
Male
Medical sciences
Metabolic diseases
Middle Aged
Miscellaneous. Osteoarticular involvement in other diseases
Other metabolic disorders
Purines and pyrimidines (gout, hyperuricemia...)
Thiazoles - therapeutic use
Treatment Outcome
Uric Acid - blood
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives. This 5-yr study assessed urate-lowering and clinical efficacy and safety of long-term febuxostat therapy in subjects with gout. The primary efficacy end-point was reduction to and maintenance of serum urate (sUA) levels
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/ken457